Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active...

Abstract

In aspirin-treated subjects with coronary artery disease, prasugrel 60/10 mg provides faster onset and greater inhibition of P2Y(12) receptor-mediated platelet aggregation than clopidogrel 600/75 mg, because of greater and more efficient generation of the active metabolite.

Keywords

MedicinePrasugrelClopidogrelAspirinActive metabolitePlatelet inhibitionCardiologyCoronary artery diseaseInternal medicineMetabolitePlateletThienopyridinePharmacology

Affiliated Institutions

Related Publications

Pharmacology of CS-747 (prasugrel, LY640315), a Novel, Potent Antiplatelet Agent with in Vivo P2Y<sub>12</sub>Receptor Antagonist Activity

Y. Niitsu , Joseph A. Jakubowski , Atsuhiro Sugidachi +1 more

CS-747 (prasugrel, LY640315) is a member of the thienopyridine class of oral platelet aggregation inhibitors that includes ticlopidine and clopidogrel. A single oral administrat...

2005 Seminars in Thrombosis and Hemostasis 233 citations

Dose Effect of Clopidogrel Reloading in Patients Already on 75-mg Maintenance Dose

Jean‐Philippe Collet , Johanne Silvain , Antoine Landivier +8 more

Background— Clopidogrel loading has mostly been studied in clopidogrel-naïve patients. Whether clopidogrel-treated patients readmitted for an acute coronary syndrome or percuta...

2008 Circulation 87 citations

Randomized Comparison of Prasugrel (CS-747, LY640315), a Novel Thienopyridine P2Y <sub>12</sub> Antagonist, With Clopidogrel in Percutaneous Coronary Intervention

Stephen D. Wiviott , Elliott M. Antman , Kenneth J. Winters +8 more

Background— Despite the current standard antiplatelet regimen of aspirin and clopidogrel (with or without glycoprotein IIb/IIIa inhibitors) in percutaneous coronary intervention...

2005 Circulation 378 citations

Inhibitory effect of clopidogrel on platelet adhesion and intimal proliferation after arterial injury in rabbits.

Jean‐Marc Herbert , A Tissinier , G. Defreyn +1 more

The possible activity of ticlopidine and its analogue clopidogrel in early atherogenesis was investigated. Incubation of rabbit platelets with the extracellular matrix produced ...

1993 Arteriosclerosis and Thrombosis A Jou... 104 citations

Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease

Tomas Jernberg , Christopher D. Payne , Kenneth J. Winters +6 more

In this population, prasugrel (40-60 mg LD and 10-15 mg MD) achieves greater IPA and a lower proportion of pharmacodynamic non-responders compared with the approved clopidogrel ...

2006 European Heart Journal 535 citations

Publication Info

Year: 2007
Type: article
Volume: 29
Issue: 1
Pages: 21-30
Citations: 455
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

455

OpenAlex

Cite This

APA Style

                            
                                
                                    Lars Wallentin, 
                                
                                    Christoph Varenhorst, 
                                
                                    Stefan James
                                
                                et al.
                            
                            (2007). 
                            Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. 
                            European Heart Journal
                            , 29
                            (1)
                            , 21-30.
                            https://doi.org/10.1093/eurheartj/ehm545
                        

Identifiers

DOI: 10.1093/eurheartj/ehm545